BC Innovations | May 12, 2011
Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Scleroderma Serotonin (5-HT2B) receptor Mouse and cell culture studies suggest that antagonizing the 5-HT2B receptor could help treat scleroderma. In...
BC Innovations | May 12, 2011
Targets & Mechanisms

Freezing fibrosis at the source

Hyperactive skin cells cause fibrosis, but targets to prevent their pathogenic activation have been hard to pin down, thus making it difficult to intervene early in disease. Now, a European team has mapped out a...
BC Week In Review | Dec 4, 2006
Clinical News

BF-1 update

By year end, Biofrontera will start an open-label, Dutch trial in 12 healthy male volunteers. Biofrontera AG (FSE:B8F), Leverkusen, Germany   Product: BF-1   Business: Neurology   Molecular target: Serotonin (5-HT2B) receptor   Description: Serotonin...
BioCentury | Nov 17, 2003

Merger ups & downs

Restructuring in Germany is slowly progressing, with companies retooling, spinning out, selling assets and merging. But while one new merger was announced last week, another fell apart - illustrating how difficult it often is to put...
Items per page:
1 - 4 of 4